Resistant Mycoplasma pneumoniae in children.

Area of Science:

• Pediatrics
• Infectious Diseases
• Microbiology

Background:

• Community-acquired pneumonia is common in children.
• Macrolide-resistant Mycoplasma pneumoniae (MRMP) is an emerging global health concern.
• Increasing MRMP rates are noted, particularly in East Asian countries.

Purpose of the Study:

• To review current evidence for treating macrolide-resistant Mycoplasma pneumoniae pneumonia in children.
• To provide treatment recommendations for pediatric MRMP cases, especially those with treatment failure or travel history.

Main Methods:

• Literature review of available evidence on MRMP treatment in pediatric populations.
• Analysis of treatment outcomes for different antibiotic classes.

Main Results:

• Tetracyclines demonstrate the strongest evidence for treating MRMP in children.
• Fluoroquinolones show more limited evidence for MRMP treatment.
• Doxycycline is recommended at 2 mg/kg twice daily (max 100 mg/dose) for MRMP.

Conclusions:

• Macrolide resistance in Mycoplasma pneumoniae is a growing worldwide issue.
• Doxycycline is the preferred treatment for pediatric MRMP, particularly in cases of treatment failure or recent travel to endemic regions.
• Prompt recognition and appropriate antibiotic selection are crucial for managing MRMP.